Navigation Links
Study Shows MS Patients at Most Risk for Drug-Linked Brain Illness
Date:5/16/2012

By Randy Dotinga
HealthDay Reporter

WEDNESDAY, May 16 (HealthDay News) -- Drug company researchers say they've determined which multiple sclerosis patients are most vulnerable to developing a rare brain infection while taking a powerful drug called Tysabri (natalizumab).

Even the multiple sclerosis patients at highest risk of developing the brain infection face low odds of getting it while on Tysabri, but the infection can be deadly.

"Now we can identify which risk group each patient is in. This will help doctors and patients make better decisions," said Dr. Gary Bloomgren, lead author of a study released Wednesday and vice president of drug safety at Biogen Idec, which makes the drug.

About 100,000 patients have taken Tysabri at least once. The drug, which is used mainly to delay the progression of multiple sclerosis, has been on the market since 2006. It originally went on the market in 2005 but was removed due to medical problems that some patients encountered, Bloomgren said.

Tysabri is expensive, costing about $40,000 a year. It dampens the immune system, potentially reducing the inflammation that is a major part of multiple sclerosis. Dampening the immune system, however, can allow an infection known as the JC virus to wreak havoc on the brain and cause a condition called progressive multifocal leukoencephalopathy.

The JC virus is extremely common, affecting about half of adults by middle age, but the immune system normally keeps it under control so it causes no symptoms. If unleashed, however, progressive multifocal leukoencephalopathy can cause cognitive problems, such as unusual behavior, paralysis and problems with vision, speech and balance, said study co-author Dr. Sandra Richman, senior medical director at Biogen Idec.

Once the symptoms appear, doctors usually advise patients to stop the treatment, she said. Progressive multifocal leukoencephalopathy often causes permanent disabi
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Study Links Antibiotic to Slight Rise in Heart Patients Death Risk
2. U.S. Assistance to Africa Cut AIDS-Related Deaths: Study
3. Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study
4. Inhaled Steroids Lead to Big Drop in Asthma Deaths at Texas Hospital: Study
5. New inflammation hormone link may pave way to study new drugs for Type 2 diabetes
6. Study highlights need for coordination of care in stage 2 and 3 rectal cancer treatment
7. 53 million Americans might have diabetes by 2025, according to a new study in Population Health Management
8. Study examines BI-RADS and MRI in predicting breast cancer
9. Self-Managing COPD Might Pose Risks, Study Suggests
10. Study finds number of battery-related emergency department visits by children more than doubles
11. UTSA study finds ovulating women perceive sexy cads as good dads
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Shows MS Patients at Most Risk for Drug-Linked Brain Illness
(Date:5/21/2013)... AURORA, Colo. (May 21, 2013) Research into genetic ... the University of Colorado School of Medicine may lead ... to a paper published online by JAMA . ... helps predict survival in some cases of pulmonary fibrosis, ... three years. As a result of the study, researchers ...
(Date:5/21/2013)... agency for scientific and technological research So Paulo Research ... announced an investment estimated in US$ 680 million to ... a period of up to eleven years, subject to ... , Funding for the 17 RIDCs will come from ... support personnel, and infrastructure). Host institutions will participate in ...
(Date:5/21/2013)... 2013 The nation’s first trial involving ... nearing its conclusion in Washington state court, Bernstein Liebhard ... yesterday, an attorney for the Plaintiffs compared Intuitive Surgical ... tie sales and services for its customers. ... control of surgeons, to keep control of hospitals and ...
(Date:5/21/2013)... City, Utah (PRWEB) May 21, 2013 ... HRA, HSA and FSA accounts. Zane Benefits, ... sponsored health benefits, is the leader in defined ... health reimbursement arrangements . , According to Zane Benefits’ ... health reform) was signed into law in 2010 and ...
(Date:5/21/2013)... Washington, DC (PRWEB) May 21, 2013 ... Solid Benefits Guidance (SBG) will identify which strategies can ... while ensuring high-quality care to the members who are ... Atlantic Information Services, Inc., “How to Manage Specialty ... , Specialty pharmaceuticals are now the main driver for ...
Breaking Medicine News(10 mins):Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2
... that points to a new strategy for preventing or possibly ... and tissue damage researchers at the University of ... molecule called Epac (Exchange protein activated by cAMP1), plays a ... The research will be published in the online edition ...
... Specialized Bicycles; Goodby, Silverstein & Partners;, and Google Challenged Participants ... ... ROCK, Ark., April 22 The William J. Clinton,Presidential Center and ... April 26., This year,s festival will host "The Aquaduct: Mobile ...
... of the Cycling Event for the,5th Consecutive Year, ... Store, America,s leading supplier of power wheelchairs and,scooters, raised ... Multiple,Sclerosis Society by participating in the MS150 bike ride., ... a Platinum Sponsor of,the two-day cycling journey from Houston ...
... Abbott (NYSE:,ABT) will present at the Morgan ... 2008. Thomas C. Freyman, executive vice,president, finance and ... company at 7:30 a.m. Central time., A ... accessible through,Abbott,s Investor Relations Web site at ...
... PA, NC, SC, GA and,FL, WEST POINT, ... not-for-profit senior living,organization, announced today that it has ... Cove, a continuing care retirement community (CCRC),in Huntsville, ... May 30., Following the closing of this ...
... in radiology and medical image and information management,solutions, today announced it will ... before the market opens on,Thursday, May 1, 2008., ... -- Thursday, May 1, 2008 ... 7:30 a.m. ...
Cached Medicine News:Health News:Scientists identify novel way to prevent cardiac fibrosis 2Health News:Clinton Center's Earth Day to Feature 'Innovate or Die Contest' Winner 2Health News:The SCOOTER Store and Their Employees Contribute $43,000 in MS150 Bike Ride to Help Texans With Multiple Sclerosis 2Health News:PA-Based ACTS Retirement-Life Communities Announces Agreement to Acquire Carlton Cove in Huntsville, Alabama 2Health News:AMICAS Schedules First Quarter 2008 Earnings Call 2
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: VASO) ... design, manufacture and sale of medical devices and in the ... Jun Ma , President and CEO of ... MicroCap Conference on Thursday, May 30, 2013 in ... The Company,s presentation is scheduled to begin ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Coherence Tomography (OCT) http://www.reportlinker.com/p01187977/Global-Markets-and-Technologies-for-Optical-Coherence-Tomography-OCT.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ...   BCC,s aim ... synopsis of the current and future characteristics ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... , Beverage Can Stay-Tabs Pose Swallowing Risk ... reports that beverage can stay-tabs pose a potential ingestion risk. ... after safety concerns about pull-tabs. The new study found 19 ... teenagers. Further, the study found that most ingested stay-tabs are ...
... , CHICAGO, Nov. 30 A large ... receive unindicated and unnecessary additional image acquisition resulting in ... today at the annual meeting of the Radiological Society ... of all physicians who work with ionizing radiation to ...
Cached Medicine Technology:Monday, Nov. 30: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 2Monday, Nov. 30: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 3Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 2Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 3
... is the cycler that revolutionized thermal cycling. ... consistent results, experiment-to-experiment and block-to-block. This rugged ... it's a platform for new features and ... thermal cycler chassis, does not include the ...
... The Gene Cycler unit is an inexpensive personal ... for the PCR process. Lightweight, with a small ... almost anywhere, including the researcher's desk. , The ... researchers who do not have access to a ...
Contains: Card, cabling and instructions to remotely access a RoboCycler® instrument from a PC or Macintosh® computer...
... Ideal for day-to-day temperature ... of 0.1C ,30% reduction ... Peltier or coolant-based cyclers ... temperature ramping ,Options for ...
Medicine Products: